Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 1, 2005, Pages

  Razonable, Raymund R ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Antivirals; Cytomegalovirus infections; Dosage schedules; Epidemiology; Immunosuppressive agents; Mortality; Resistance; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; FOSCARNET; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; VIRUS REPLICATION;

EID: 17444431146     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.suppl_1.s7     Document Type: Conference Paper

References (44)

1. Schnitzler MA, Lowell JA, Hardinger KL et al. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant. 2003; 3:445-51.
2. Paya CV, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:298-325.
3. Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001; 184:1461-4.
4. Razonable RR, van Cruijsen H, Brown RA et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Inject Dis. 2003; 187:1801-8.
5. Sia IG, Wilson JA, Groettum CM et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000; 181:717-20.
6. Mendez JC, Dockrell DH, Espy MJ et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis. 2001; 183:179-84.
7. Portela D, Patel R, Larson-Keller JJ et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis. 1995; 171:1014-8.
8. Bailey TC, Powderly WG, Storch GA et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis. 1993; 21:196-201.
9. Hanto DW, Jendrisak MD, So SK et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation. 1994; 57:377-84.
10. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004; 103:2003-8.
11. Singh N. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2003. Abstract V-1286.
12. McEvoy GK, ed. Sirolimus. In: AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists; 2004:3644-7.
13. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999; 67:1036-42.
14. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000; 69:1252-60.
15. Eisen HJ, Tuzcu EM, Dorent R et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003; 349:847-58.
16. McEvoy GK, ed. Daclizumab. In: AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists; 2004:3639-41.
17. Nashan B, Light S, Hardie IR et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 1999; 67:110-5.
18. Hengster P, Pescovitz MD, Hyatt D et al. Roche Study Group. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Transplantation. 1999; 68:310-3.
19. Ekberg H, Backman L, Tufveson G et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int. 2000; 13:151-9.
20. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2:48-56.
21. Ponticelli C, Yussim A, Cambi V et al. Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 2001; 72:1261-7.
22. Adu D, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ. 2003; 326:789.
23. Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101:3413-5.
24. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002; 99:4357-63.
25. Perez-Simon JA, Kottaridis PD, Martino R et al. Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002; 100: 3121-7.
26. Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis. 2002; 185:854-60.
27. Gane E, Saliba F, Vablecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet. 1997; 350:1729-33.
28. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611-20.
29. Razonable RR, Brown RA, Hart GD et al. Late-onset cytomegalovirus (CMV) disease in solid organ transplant recipients: risk stratification based on serology, viral load and allograft status. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2003. Abstract.
30. Shibolet O, Ilan Y, Kalish Y et al. Late cytomegalovirus disease following liver transplantation. Transpl Int. 2003; 16:861-5.
31. Slifkin M, Tempesti P, Poutsiaka DD et al. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis. 2001; 33:E62-8.
32. Jochimsen F, Westhoff T, Engelmann E et al. Late-onset cytomegalovirus reactivation in critically ill renal transplant patients. Transplantation. 2003; 76:430-2.
33. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis. 1997; 176:782-5.
34. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999; 28:618-23.
35. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003; 101:407-14.
36. Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000; 25:757-63.
37. Ozdemir E, St John LS, Gillespie G et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood. 2002; 100:3690-7.
38. Wang FZ, Larsson K, Linde A et al. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2002; 30:521-6.
39. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356:645-9.
40. Boivin G, Gilbert C, Gaudreau A et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001; 184:1598-602.
41. Boivin G. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2002. Abstract.
42. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes. 2003; 10:60-5.
43. Bhorade SM, Lurain NS, Jordan A et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002; 21:1274-82.
44. Isada CM, Yen-Lieberman B, Lurain NS et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis. 2002; 4:189-94.